✦ LIBER ✦

OP0253 The JAK Inhibitor Tofacitinib Suppresses Synovial JAK1-STAT1 Signalling in Rheumatoid Arthritis

✍ Scribed by Boyle, D. L.; Wei, N.; Singhal, A. K.; Rosengren, S.; Kaplan, I.; Soma, K.; Hodge, J.; Luo, Z.; Krishnaswami, S.; Gruben, D.; Zwillich, S. H.; Bradley, J.; Firestein, G. S.

Book ID: 123606917
Publisher: BMJ Publishing Group
Year: 2013
Tongue: English
Weight: 363 KB
Volume: 72
Category: Article
ISSN: 0003-4967
DOI: 10.1136/annrheumdis-2013-eular.458

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6643 Anti-proliferative effect of SOCS-1

6643 Anti-proliferative effect of SOCS-1,-3 through the suppression of JAK/STAT and P38 MAPK signaling pathways in gastric cancer cells

✍ Souma, Y.; Nishida, T.; Takahashi, T.; Serada, S.; Mori, M.; Doki, Y.; Naka, T. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Trichostatin A, a histone deacetylase in

Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells

✍ Hua Xiong; Wan Du; Yan-Jie Zhang; Jie Hong; Wen-Yu Su; Jie-Ting Tang; Ying-Chao 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 882 KB

## Abstract Aberrant janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling is involved in the oncogenesis of several cancers. Suppressors of cytokine signaling (SOCS) genes and SH2‐containing protein tyrosine phosphatase 1 (SHP1) proteins, which are negative regulator

PP-051 Curcumin suppresses the induction

PP-051 Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the JAK PKC-δ STAT1 signaling pathway in IFN-γ-stimulated murine dendritic cells

✍ J.W. Park; Y.-I. Jeong; Y.-M. Park 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Phase IIb dose-ranging study of the oral

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

✍ Roy Fleischmann; Maurizio Cutolo; Mark C. Genovese; Eun Bong Lee; Keith S. Kanik 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 4 views

A phase IIb dose-ranging study of the or

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

✍ Joel M. Kremer; Stanley Cohen; Bethanie E. Wilkinson; Carol A. Connell; Jonathan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB